Evidence map›Paper›PMID 38046043›Full record

ReviewClinical kidney journal2023

Management of hypertension in patients with cancer: challenges and considerations.

Shubhi Pandey, Amar Kalaria, Kenar D Jhaveri, Sandra M Herrmann, Agnes S Kim

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Observational
  6. Review
  7. The Japanese Society of Hypertension Guidelines for the management of elevated blood pressure and hypertension 2025 (JSH2025).Hypertension research : official journal of the Japanese Society of Hypertension · 2026
    Article
  8. Article
  9. Navigating the Complexities of Cancer Treatment-Induced Hypertension.Journal of cardiovascular development and disease · 2025
    Review
  10. Ten tips for an onco-nephrology clinic.Clinical kidney journal · 2025
    Review
  11. Article
  12. Article
  13. Article
  14. Cardiovascular disease and lung cancer.Frontiers in oncology · 2024
    Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shubhi PandeyDepartment of Internal Medicine, Calhoun Cardiology Center, University of Connecticut Health, Farmington, CT, USA.
Amar KalariaUniversity of Connecticut School of Medicine, Farmington, CT, USA.
Kenar D JhaveriDivision of Kidney Diseases and Hypertension, Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, USA.ORCID https://orcid.org/0000-0003-1578-0524
Sandra M HerrmannDivision of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA.
Agnes S KimDepartment of Internal Medicine, Calhoun Cardiology Center, University of Connecticut Health, Farmington, CT, USA.ORCID https://orcid.org/0000-0002-7487-9340

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The survival rates of many cancers have significantly improved due to recent advancements in cancer screening and therapeutics. Although better cancer outcomes are encouraging, additional health challenges have surfaced, the utmost of which is the burden imposed by various cardiovascular and renal toxicities of anticancer therapies. To improve the overall outcome of patients with cancer, it is essential to understand and manage these treatment-related adverse effects. The cardiovascular side effects of antineoplastic therapies are well-known and include left ventricular dysfunction, heart failure, myocardial ischaemia, QT prolongation, arrhythmia and hypertension. Among these, hypertension is the most common complication, prevalent in about 40% of all cancer patients, yet frequently overlooked and undertreated. This review explores the intricate connection between cancer and hypertension and provides distinct approaches to diagnosing, monitoring and managing hypertension in patients with cancer. We also outline the challenges and considerations that are relevant to the care of patients receiving anticancer drugs with prohypertensive potential.

Indexed as

blood pressure managementcancercardio-oncologyonco-hypertensiononco-nephrologyVEGF signalling pathway inhibitors

Identifiers

PMID38046043
PMCPMC10689173

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.